285 related articles for article (PubMed ID: 21277100)
1. Effect of whole pelvic radiotherapy for patients with locally advanced prostate cancer treated with radiotherapy and long-term androgen deprivation therapy.
Mantini G; Tagliaferri L; Mattiucci GC; Balducci M; Frascino V; Dinapoli N; Di Gesù C; Ippolito E; Morganti AG; Cellini N
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e721-6. PubMed ID: 21277100
[TBL] [Abstract][Full Text] [Related]
2. Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma.
Aizer AA; Yu JB; McKeon AM; Decker RH; Colberg JW; Peschel RE
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1344-9. PubMed ID: 19464821
[TBL] [Abstract][Full Text] [Related]
3. Extreme-risk prostate adenocarcinoma presenting with prostate-specific antigen (PSA)>40 ng/ml: prognostic significance of the preradiation PSA nadir.
Alexander AS; Mydin A; Jones SO; Christie J; Lim JT; Truong PT; Ludgate CM
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e713-9. PubMed ID: 21277102
[TBL] [Abstract][Full Text] [Related]
4. High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes.
Edelman S; Liauw SL; Rossi PJ; Cooper S; Jani AB
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1473-9. PubMed ID: 22245201
[TBL] [Abstract][Full Text] [Related]
5. Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy.
Deville C; Vapiwala N; Hwang WT; Lin H; Ad VB; Tochner Z; Both S
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1389-96. PubMed ID: 21664069
[TBL] [Abstract][Full Text] [Related]
6. Whole-pelvis radiotherapy in combination with interstitial brachytherapy: does coverage of the pelvic lymph nodes improve treatment outcome in high-risk prostate cancer?
Bittner N; Merrick GS; Wallner KE; Butler WM; Galbreath R; Adamovich E
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1078-84. PubMed ID: 19553031
[TBL] [Abstract][Full Text] [Related]
7. What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?
Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg DF; Pollack A
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1003-10. PubMed ID: 15752879
[TBL] [Abstract][Full Text] [Related]
8. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
[TBL] [Abstract][Full Text] [Related]
9. Lack of benefit of pelvic radiation in prostate cancer patients with a high risk of positive pelvic lymph nodes treated with high-dose radiation.
Vargas CE; Galalae R; Demanes J; Harsolia A; Meldolesi E; Nürnberg N; Schour L; Martinez A
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1474-82. PubMed ID: 15964706
[TBL] [Abstract][Full Text] [Related]
10. Long-term results after high-dose radiotherapy and adjuvant hormones in prostate cancer: how curable is high-risk disease?
Zapatero A; García-Vicente F; Martín de Vidales C; Cruz Conde A; Ibáñez Y; Fernández I; Rabadán M
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1279-85. PubMed ID: 20932659
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of a prospective trial of trimodality therapy of weekly paclitaxel, radiation, and androgen deprivation in high-risk prostate cancer with or without prior prostatectomy.
Hussain A; Wu Y; Mirmiran A; DiBiase S; Goloubeva O; Bridges B; Mannuel H; Engstrom C; Dawson N; Amin P; Kwok Y
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):167-74. PubMed ID: 21036487
[TBL] [Abstract][Full Text] [Related]
12. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
13. Redefining high-risk prostate cancer based on distant metastases and mortality after high-dose radiotherapy with androgen deprivation therapy.
Tendulkar RD; Reddy CA; Stephans KL; Ciezki JP; Klein EA; Mahadevan A; Kupelian PA
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1397-404. PubMed ID: 21665379
[TBL] [Abstract][Full Text] [Related]
14. External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcome.
Martínez-Monge R; Moreno M; Ciérvide R; Cambeiro M; Pérez-Gracia JL; Gil-Bazo I; Gaztañaga M; Arbea L; Pascual I; Aristu J
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e469-76. PubMed ID: 22284039
[TBL] [Abstract][Full Text] [Related]
15. Survival Outcomes of Whole-Pelvic Versus Prostate-Only Radiation Therapy for High-Risk Prostate Cancer Patients With Use of the National Cancer Data Base.
Amini A; Jones BL; Yeh N; Rusthoven CG; Armstrong H; Kavanagh BD
Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1052-63. PubMed ID: 26581142
[TBL] [Abstract][Full Text] [Related]
16. Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results.
Lim TS; Cheung PC; Loblaw DA; Morton G; Sixel KE; Pang G; Basran P; Zhang L; Tirona R; Szumacher E; Danjoux C; Choo R; Thomas G
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):85-92. PubMed ID: 18355982
[TBL] [Abstract][Full Text] [Related]
17. Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome.
Zilli T; Jorcano S; Escudé L; Linero D; Rouzaud M; Dubouloz A; Miralbell R
Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):316-22. PubMed ID: 24667210
[TBL] [Abstract][Full Text] [Related]
18. Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era?
Castle KO; Hoffman KE; Levy LB; Lee AK; Choi S; Nguyen QN; Frank SJ; Pugh TJ; McGuire SE; Kuban DA
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):693-9. PubMed ID: 22836052
[TBL] [Abstract][Full Text] [Related]
19. High-dose adjuvant radiotherapy after radical prostatectomy with or without androgen deprivation therapy.
Ost P; Cozzarini C; De Meerleer G; Fiorino C; De Potter B; Briganti A; Nagler EV; Montorsi F; Fonteyne V; Di Muzio N
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):960-5. PubMed ID: 22172901
[TBL] [Abstract][Full Text] [Related]
20. Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease.
Stenmark MH; Blas K; Halverson S; Sandler HM; Feng FY; Hamstra DA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e335-44. PubMed ID: 21645976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]